Currently, six disease-modifying drugs (DMD) for multiple sclerosis are available in Japan: subcutaneous interferon-b-1b, intramuscular interferon-b-1a, glatiramer acetate, natalizumab, fingolimod and dimethyl fumarate. These drugs have different clinical and adverse effects. Therefore, it is critical to select the appropriate DMD, and switching from one DMD to another in clinical practice requires careful monitoring. The Japanese guidelines for multiple sclerosis and neuromyelitis optica were revised in 2017, and a supplement to the guidelines for dimethyl fumarate was published in 2018. Herein, we review the characteristics of the six DMD available in Japan, and discuss their use according to the Japanese guidelines.
Introduction
Multiple sclerosis (MS) is a major inflammatory demyelinating disease of the central nervous system. Several phenotypes of MS are recognized based on the past course of the disease. Currently, the United States National Multiple Sclerosis Society and the Multiple Sclerosis International Federation categorize the phenotypes into four types: 1 
clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS).
At present, >10 different disease-modifying drugs (DMD) for MS are available in Western countries in different administration forms. In Japan, six DMD are currently available, namely, subcutaneous (SC) interferon (IFN)b-1b, intramuscular (IM) IFNb-1a, glatiramer acetate (GA), natalizumab, fingolimod and dimethyl fumarate (DMF). These active ingredients differ in terms of administration routes, efficacy (suppression of clinical relapses and prognosis of disease severity) and distinctive adverse effects. The Japanese guidelines for MS and neuromyelitis optica were revised in 2017, 2 and a supplement to the guidelines regarding DMF was released in 2018. 3 These guidelines are intended for physicians and nurses, as well as for patients and their family. 2, 4 Therefore, the 2017 guidelines provide important information regarding medical and social support resources, disability and treatment outcome assessments, rehabilitation, and symptomatic treatment, in addition to recent advances in pathogenesis understanding, treatments and epidemiology information. 4 The present review summarizes the current information on the six DMD available in Japan, and discusses their use based on the Japanese guidelines.
Interferon-b
Large clinical trials of IFNb for MS carried out in Western countries were reported in the 1990s. 5, 6 In Japan, a randomized, double-blinded clinical study of IFNb-1b SC showed similar effects of this drug, such as reduction of relapse rates and change in magnetic resonance imaging (MRI) lesion area, in Japanese patients with RRMS. 7 Regarding IFNb-1a IM, an open study showed that the median number of gadolinium (Gd)-enhanced lesions decreased from 2.5 to 0.3 (P < 0.0001) compared with the pre-treatment values. 8 IFNb-1b SC and IFNb-1a IM were approved in September 2000 and July 2006, respectively, in Japan, almost 10 years after their approval in Europe and USA. These drugs have not been approved for CIS in Japan, although data on the efficacy of IFNb were reported for patients with CIS treated with this drug. 9, 10 Regarding the two progressive forms of MS, the effects of IFNb for PPMS have not been proven, and some efficacy for SPMS patients with relapses and/or disease activities evaluated by MRI was reported. 2 The notable adverse effects of IFNb-1b SC and IFNb-1a IM are similar, and include flu-like symptoms, injection site reaction, liver dysfunction, leukopenia, lymphocytopenia, depression, suicide attempts and interstitial pneumonitis. 2, 4 To reduce adverse events, such as flu-like symptoms, specific interventions, such as dose titration, analgesia and optimal injection timing, would be effective. [10] [11] [12] Sho-saiko-to was identified as a contraindicated drug for combined use with IFNb. 2, 4 Following drug approvals, reports on disease exacerbations after IFNb induction were published in cases of the optic-spinal form of MS. 13, 14 Currently, most cases with the optic-spinal form of MS are considered distinct from MS and are known as neuromyelitis optica spectrum disorders. Overall, in the 2017 guidelines, treatment with IFNb is not recommended for patients positive for the anti-aquaporin4 (anti-AQP-4) antibody specific for neuromyelitis optica spectrum disorders. 2 
GA
In the USA, the Food and Drug Administration approved GA for decreasing the frequency of relapses, but not for reducing the progression of disability. A Cochrane review on GA reported that the reduction of the mean number of relapses was evident at 1 year (À0.35), 2 years (À0.51) and 35 months (À0.64). 15 In Japan, a phase II, multicenter, open-label, single-arm, 52-week study of GA in MS patients showed a reduction in the number of new Gdenhanced and T2 lesions, as well as a 42% reduction of the annualized relapse rates compared with those observed 1 year before treatment. 16 Although the number of patients was small (13 for the analysis), GA was approved for MS in September 2015 in Japan, almost 20 years after its approval in USA. Furthermore, there has been no evidence that GA is effective for PPMS.
The most common systemic adverse event was a transient and self-limiting patterned reaction of flushing, chest tightness, sweating, palpitations and anxiety. Local injection site reactions were observed in up to 50% of patients treated with GA, thus making a blind assessment of outcomes questionable. 15 The notable adverse effects of GA reported in the Japanese guidelines include injection site, immediate post-injection and hypersensitivity reactions. 2, 4 In addition, this drug has been deemed safe for longterm administration. 2 
Fingolimod
Two global clinical trials of fingolimod for RRMS; that is, the FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREE-DOMS) study 17 and Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS) study, 18 showed a significant reduction of relapse rates. The FREE-DOMS study also showed that fingolimod significantly inhibited disability progression in patients with RRMS. 17 A 6-month clinical study in Japan carried out to evaluate the efficacy of fingolimod relative to a placebo in Japanese patients with relapsing MS showed that MRI lesion activity and annualized relapse rates were consistently reduced with fingolimod treatment. 19 Fingolimod was approved in September 2011 in Japan as the first oral DMD.
Notable adverse effects of fingolimod include sinus bradycardia at the initial dose, varicella zoster virus infection, progressive multifocal leukoencephalopathy (PML) infection, Cryptococcus infection, liver dysfunction, macular edema and malignant tumors. 2, 4 Several drugs are contraindicated for combined use with fingolimod: live vaccine, class Ia antiarrhythmic drugs and class III antiarrhythmic drugs. 2, 4 In Japan, four cases with PML related to fingolimod treatment have been reported as of July 2018, in addition to 17 cases reported as of May 2018 worldwide (Novartis Pharma, personal communication). In addition, several cases with exacerbations of disease were reported after initiation of fingolimod in patients positive for anti-AQP4 antibodies. Thus, those positive for anti-AQP4 antibody or those with neuromyelitis optica spectrum disorders should not be treated with fingolimod. 2, 4 Careful follow up is required in patients who discontinue fingolimod, because cases with disease exacerbations or rebound were identified after withdrawal of fingolimod and after the switch from fingolimod to another DMD. 20 
DMF
Two placebo-controlled, phase III clinical trials; that is, the Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting Multiple Sclerosis (DEFINE) study 21 and Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis (CONFIRM) study, 22 established the efficacy of DMF in decreasing relapses in patients with RRMS. Likewise, the global phase III clinical trial, a multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of DMF in patients with relapsing MS (APEX study), which involved Asian countries (Japan, Korea and Taiwan) and Eastern European countries (Poland and the Czech Republic), proved the efficacy of DMF. 23 DMF was approved in December 2016 in Japan as the second oral DMD. A multicenter, randomized, doubleblinded, placebo-controlled, phase III study of the efficacy and safety of BG00012 oral DMF in delaying progression of disability in patients with SPMS (INSPIRE study) was suspended in the early stage, and no data are available.
Notable adverse effects of DMF include flushing and gastrointestinal events, such as nausea, vomiting, diarrhea, upper abdominal pain and dyspepsia. Flushing accompanied by itching and burning sensations has an incidence of 22-38% based on previous clinical trials. [21] [22] [23] Additional adverse events are lymphopenia, leucopenia, infection including PML (five PML cases worldwide globally as of July 2018 and no case in Japan; Biogen Japan, personal communication), acute renal failure, liver injury and anaphylaxis. Moderate-to-severe lymphopenia might increase PML risk, and it is recommended to obtain a complete blood count before the treatment and to monitor the lymphocyte count for, at least, every 3 months during the DMF treatment. 3, 24 In addition, it is recommended that DMF be suspended when lymphopenia (<500/mm 3 ) lasts >6 months.
3,24

Natalizumab
Two global phase III clinical trials; that is, the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) 25 and Safety and Efficacy of Natalizumab in Combination With Interferon Beta1a in Patients With Relapsing-Remitting Multiple Sclerosis (SENTINEL) 26 studies, showed significant efficacy in reducing clinical relapse rates and risk of sustained progression of disability. In Japan, a multicenter, phase II study showed that natalizumab treatment was well tolerated, and reduced relapses and the development of new brain lesions in Japanese RRMS patients. 27 Natalizumab was approved in March 2014 in Japan, almost 10 years after its approval in the USA. Its effects against PPMS and SPMS are not available.
2 Natalizumab is not considered to control disease activity in patients positive for anti-AQP4 antibodies, 28 and those positive for anti-AQP4 antibody should not be treated with natalizumab. 2, 4 Notable adverse effects of natalizumab include infusion reaction, allergic reaction and PML. In particular, the risk of PML after natalizumab treatment has been stratified by anti-John Cunningham (JC) virus antibody status as the highest risk factor, along with previous immunosuppressant use. 29 Overall, it is recommended to check the presence of anti-JC virus antibody before initiating natalizumab administration, and to thoroughly discuss the risk of natalizumab treatment with patients and their families. 2, 28 Globally, 781 cases of patients with PML related to natalizumab have been reported, including two cases in Japan, as of June 2018 (Biogen Japan, personal communication). Because no treatments for PML have been established to date, detecting PML in the early stages of the disease is critical. Furthermore, careful follow up is required in patients treated with natalizumab, especially in those positive for anti-JC virus antibodies. These patients should undergo an MRI examination every 3-4 months. 2, 4 There have been cases with disease exacerbations or rebound after withdrawal of natalizumab or switch from natalizumab to another DMD, highlighting the importance of careful follow up of patients who discontinue natalizumab. 30 
Positioning of each DMD and treatment strategy
IFNb-1b SC, IFNb-1a IM and GA are first-line DMD according to the 2017 Japanese guidelines, and fingolimod is considered a second-line DMD.
2,4 Natalizumab is a second-line treatment option for MS patients negative for anti-JC virus antibody, and a third-line option for MS patients positive for anti-JC virus antibody. 2, 4 Regarding effectiveness and longterm safety, the guidelines recommend initiation of treatment with the first-line approved drugs that are injectable. 2, 4 However, the guidelines have not determined the positioning of DMF yet, because long-term safety data are missing. 3, 24 Post-marketing data from Italy showed a better clinical and radiological outcome in treatment-na€ ıve patients (started DMF as first treatment) compared with patients who switched from other DMD to DMF. 31 The positioning of this drug in Japan will be determined after longterm efficacy and safety are available.
Although there are no standardized criteria to discriminate a suboptimal responder from a nonresponder to a prescribed DMD, efficacy can be assessed by the annualized relapse rate, disability progression and change in MRI findings within 1 year of treatment. 2, 4 Furthermore, non-responder definition and guidelines for switching DMD were proposed by the Canadian MS Working Group, 32, 33 and the Rio score 34 was introduced in the 2017 Japanese guidelines.
2 When a prescribed DMD is judged ineffective, it should be either substituted with another first-line drug or switched with a second-line (fingolimod or natalizumab for anti-JC virus antibody-negative patients) or third-line (natalizumab for anti-JC virus antibody-positive patients) drug. 2, 4 This stepwise use of DMD, wherein the safety risk increases with stronger potency for suppression of MS disease activity, is termed as escalation therapy. 2, 4 While switching between first-line drug therapies, a Cochrane Collaboration methodology-based study reported reliable data comparing IFNb and GA, and concluded the two therapies do not seem to differ in terms of clinical efficacy and safety, although IFN was found to limit the increase of MRI lesion burden more than GA. 35 With similar safety and efficacy in the prevention of disease activity, clinicians can select a therapy preferable for their patient based on MRI measures and tolerability differences. 35 Highly active disease in MS patients is defined as more than two clinical relapses within the previous 12 months, two separate MRI scans showing more than a few Gd-enhancing lesions and/or new or enlarging T2 lesions, and rapid progression of the Expanded Disability Status Scale score. 2, 4 In patients with high disease activities, treatment initiation with a second-or third-line DMD might be required, because the window of opportunity for the efficacy of a DMD can be narrow in such patients and the escalation therapy might waste treatment time. 2, 4 Usually, a few months are required to benefit from a DMD treatment, such as reduction of clinical relapse or activities in MRI. Thus, it is not reasonable to switch to another DMD in the early stage of the initiation of a DMD based only on clinical relapses and/or new/enlarged T2 or Gd-enhanced lesions in MRI.
In patients with RRMS, early introduction of a DMD is strongly recommended by the 2017 Japanese guidelines, because irreversible lesions increase over time. 2, 4 However, DMD therapies for patients with CIS are still controversial. Regarding the progressive type of MS, patients with disease activities should be evaluated by clinical relapses and/or MRI to determine the appropriate DMD. The choice of DMD for each patient would be based on disease activity, socioeconomic status and living environment.
Furthermore, safety, adherence and tolerability should be considered.
Conclusions
The data from clinical trials suggest that patients who are given early treatment with DMD have better outcomes than those for whom treatment is delayed. In Japan, six DMD are currently available, and the choice of DMD for an MS patient can be affected not only by disease activity, but also by cultural and social background, justifying the presence of country-specific guidelines. The 2017 Japanese guidelines for MS and neuromyelitis optica, and the supplement of the guidelines for DMF are helpful for physicians, patients with MS and their families in selecting a DMD.
